Barclays on U.S. Specialty Pharmaceuticals: Muddling Now, but Opportunity Remains
Tweet Send to a FriendGet Alerts MYL Hot Sheet
Price: $31.40 +2.28%
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade MYL Now!
Barclays on U.S. Specialty Pharmaceuticals: Muddling Now, but Opportunity Remains
Analyst, Douglas D. Tsao, said, "We continue to see long-term opportunity for the major generics makers in Europe, notably Mylan (NYSE: MYL), TEVA (Nasdaq: TEVA) & Watson (NYSE: WPI) post-Actavis closing, and, perhaps most importantly, early evidence that competitive dynamics are breaking in their favor, despite continued near-term headwinds which are forcing them to muddle through."
Tsao notes that despite investor controversy, Europe offers opportunities for MYL and TEVA, considering recent acquisitions in those markets by these companies. WPI is playing catch up. He also noted that 80% of all U.S. prescriptions are generic and 50% throughout Europe.
As far as pricing goes, Tsao does note the concern that there will be additional price cuts in certain markets, but it looks like the worst is now behind us. And, even though investors are split, Barclays is in the camp that feels Europe represents a long-term opportunity.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Douglas D. Tsao, said, "We continue to see long-term opportunity for the major generics makers in Europe, notably Mylan (NYSE: MYL), TEVA (Nasdaq: TEVA) & Watson (NYSE: WPI) post-Actavis closing, and, perhaps most importantly, early evidence that competitive dynamics are breaking in their favor, despite continued near-term headwinds which are forcing them to muddle through."
Tsao notes that despite investor controversy, Europe offers opportunities for MYL and TEVA, considering recent acquisitions in those markets by these companies. WPI is playing catch up. He also noted that 80% of all U.S. prescriptions are generic and 50% throughout Europe.
As far as pricing goes, Tsao does note the concern that there will be additional price cuts in certain markets, but it looks like the worst is now behind us. And, even though investors are split, Barclays is in the camp that feels Europe represents a long-term opportunity.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Even With 'Fairy Tale' Year, JCPenney (JCP) is Too Expensive - Analyst
- UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
Create E-mail Alert Related Categories
Analyst Comments, Retail SalesRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
